ChemiCare is an innovative SME founded in December 2016, with a commitment to the discovery and development of orphan drugs for patients affected by calcium-related genetic diseases. The company's mission is to improve the quality of life for patients suffering from rare diseases such as Duchenne Muscular Dystrophy and Tubular Aggregate Myopathies, as well as autoimmune disorders, by developing a therapy that restores abnormal intracellular calcium levels, a common feature of these diseases.
Specializing in the Health Care and Pharmaceutical industries, ChemiCare is headquartered in Italy. Their last investment of €71.43K was a grant investment received on 01 January 2019, with the EASME - EU Executive Agency for SMEs serving as the investor.
ChemiCare's dedication to developing cutting-edge drugs for calcium-related diseases reflects their commitment to addressing unmet medical needs. Their focused approach and attention to rare diseases make them a noteworthy prospect for potential venture capital investment.
Funding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Grant | €71.43K | 1 | EASME - EU Executive Agency for SMEs | 01 Jan 2019 |
No recent news or press coverage available for ChemiCare | It's a rare thing to care.